UC Davis Comprehensive Cancer Center, Sacramento, CA
Jonathan W. Riess , Susan G. Groshen , Karen L. Reckamp , Heather A. Wakelee , Geoffrey R. Oxnard , Sukhmani Kaur Padda , Marianna Koczywas , Zofia Piotrowska , Lynette M. Sholl , Cloud P. Paweletz , Christie J. Lau , Jill Kolesar , Philip C. Mack , Jeffrey Moscow , Pasi A. Janne , Primo Lara Jr., Edward M. Newman , David R. Gandara
Background: Osi (3rd gen EGFR TKI) has robust activity in 1st line EGFR mutant NSCLC and TKI resistant T790Mpos NSCLC but progressive disease (PD) occurs and outcomes with Osi alone are poor in T790Mneg, C797Xpos and EGFR exon 20 insertion (ins20) disease. This study examined the EGFR monoclonal antibody Neci with Osi in select settings of EGFR TKI resistance. Methods: Using a 3+3 design, Neci was examined in advanced EGFR mutant NSCLC at dose levels (DL) of 600 mg (DL1) & 800 mg (DL2) D1, D8 IV q21 days + Osi 80 mg qd. Four expansion cohorts (ExC; 18 each) included: A) T790Mneg PD on 1st/2nd gen TKI as last therapy, B) T790Mneg PD on 3rd gen TKI, C) T790Mpos PD on 3rd gen TKI, D) EGFR ex20ins PD on chemotherapy. Central T790M testing by ddPCR in ExC A-C. Additional studies performed include: NGS panel of > 400 genes, EGFR FISH, plasma for PK and serial EGFR ctDNA by ddPCR as exploratory analyses. Adverse events (AEs) graded (Gr) by CTCAEv5 with ORR and PFS by RECIST 1.1. Results: Dose escalation and ExC B completed accrual. In total 55 pts were evaluable (Table). 1 pt had DLT at DL2, Gr 3 sinus bradycardia. Drug related Gr 3 AEs were seen in 27% (15) of pts, mainly rash (7;13%). ctDNA showed decreased mutant allele frequency with therapy in all pts studied with detected EGFR at baseline, with complete plasma clearance in a pt with detectable C797S. Conclusions: The RP2D (Osi 80 mg qd and Neci 800 mg D1, D8 IV on q21d cycle) is feasible and tolerable. In ExC A,T790Mneg pts with 1st/2nd gen EGFR TKI as last treatment, using curtailed sampling, the pre-specified efficacy signal was reached for Osi + Neci comparing favorably to Osi alone in analogous pts from the AURA trial. Clinical activity was also seen in EGFR-dependent resistance (T790Mpos C797Spos) after PD on 3rd gen TKI and in EGFR ins 20. Clinical trial information: NCT02496663
ORR (N, %) | Median PFS (95% CI) months | ||
---|---|---|---|
PD on 1st or 2nd gen TKI | 6/21 (29%) | 4.1 (2.5, 8.5) | |
T790Mneg**1st or 2nd gen TKI as last therapy | 4/18 (22%) | 3.9 (1.3, 8.3) | |
T790Mpos | 0/1 (0%) | ||
T790Munk | 2/2 (100%) | ||
PD on 3rd gen TKI | 4/30 (13%) | 2.5 (1.3, 5.3) | |
T790Mneg | 0/19 (0%) | 1.5 (1.1, 2.6) | |
T790Mpos | 4/10 (40%) | 5.3 (2.3, 7.5) | |
T790Munk | 0/1 (0%) | ||
T790Mpos/C797Spos | 2/4 (50%) | 6.4 | |
EGFR ins 20 | 2/4 (50%) | 5.3 |
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2022 ASCO Annual Meeting
First Author: Jonathan W. Riess
2023 ASCO Annual Meeting
First Author: Xiuning Le
2024 ASCO Annual Meeting
First Author: Shen Zhao
2023 ASCO Annual Meeting
First Author: Amin Nassar